For decades, schizophrenia outcomes were measured almost entirely by symptom scales — PANSS, BPRS, SAPS, SANS. A patient could be "in remission" by these measures and still be unable to leave the house, hold a job, or sustain a friendship. The growing emphasis in modern psychiatry on recovery as a goal, supported by groups like SAMHSA, has put functional measurement at the centre of how we ask whether treatment is working. The Work and Social Adjustment Scale (WSAS) and several alternatives are the instruments that try to do that.
Functional scales measure the impact of mental illness on daily life — work, household activities, social leisure, private leisure, and close relationships — separately from symptom severity.
The WSAS
The WSAS was developed by Mundt and colleagues and published in the British Journal of Psychiatry in 2002. It is a five-item self-report scale, each item rated 0 (no impairment) to 8 (very severe impairment), giving a total range of 0–40. The five domains:
- Ability to work (paid or unpaid)
- Home management (cleaning, cooking, shopping, paying bills)
- Social leisure activities (with other people)
- Private leisure activities (alone)
- Family and relationships (close relationships)
Common interpretive thresholds, published in the original paper:
- WSAS < 10 — subclinical, no significant impairment
- WSAS 10–20 — significant functional impairment
- WSAS > 20 — moderate to severe impairment
Why the WSAS matters
It is short, free, and self-report — meaning it can be filled out in a waiting room or on a phone in two minutes. It maps onto life domains that patients actually care about. It is sensitive to change with both medication and psychosocial treatment. It has been used in major trials of CBT for psychosis, supported employment, and family interventions.
Its main limitation in schizophrenia is that severe negative symptoms can blunt insight into impairment, so a patient with profound avolition may rate their leisure as a 0 ("no impairment") because they do not consider themselves to be missing anything. Pairing WSAS self-report with a brief clinician check, or with collateral input from family, helps with this.
The PSP — Personal and Social Performance Scale
The Personal and Social Performance Scale (PSP), developed by Morosini and colleagues in 2000, is a clinician-rated functional scale designed specifically for severe mental illness. It rates four domains:
- Socially useful activities (work, study)
- Personal and social relationships
- Self-care
- Disturbing and aggressive behaviours
Each domain is rated as absent, mild, manifest, marked, severe, or very severe. The combination yields a single score from 0 to 100, with higher scores meaning better functioning. It is widely used in European trials and has become the most common functional outcome in schizophrenia long-acting injection trials.
The GAF and SOFAS
The Global Assessment of Functioning (GAF) was an axis-V rating in DSM-IV, scoring 0–100 on a single combined symptom-and-functioning continuum. DSM-5 dropped it because the symptom and functioning components were entangled. The Social and Occupational Functioning Assessment Scale (SOFAS), an 0–100 functioning-only variant, is still in use, particularly in research where a single number is needed for stratification.
The HoNOS
In NHS practice in the UK, the Health of the Nation Outcome Scales (HoNOS) — a 12-item clinician rating covering behaviours, impairments, symptoms, and social problems — is the standard outcome measure for adult mental health services. It is used routinely in case management. It is less precise than the PSP but operationally simpler and more comprehensive.
Other recovery-oriented measures
- Quality of Life Scale (QLS) — Heinrichs–Carpenter, 21 items, often used in schizophrenia drug trials
- Manchester Short Assessment of Quality of Life (MANSA) — 16-item self-report
- Recovery Assessment Scale (RAS) — measures personal recovery, including hope, identity, meaning, and personal control
- Process of Recovery Questionnaire (QPR) — developed with service-user collaboration, increasingly used in early-psychosis services
How these scales are used together
Modern early-psychosis programs (CSC, EIP) typically combine:
- A symptom scale (PANSS or BPRS-E)
- A functional scale (PSP or WSAS)
- A recovery-oriented self-report (QPR or RAS)
- A depression measure (CDSS)
- A medication-side-effect scale (UKU or Glasgow)
This bundle gives a multidimensional view that no single scale could provide.
What this means for patients and families
If your clinician focuses only on symptom scales, ask whether functional outcomes are also being tracked. The point of treatment is not just lower symptom scores; it is being able to work, study, sustain relationships, and care for oneself. The WSAS and PSP exist precisely so that the conversation can include those things explicitly.
You can complete a WSAS yourself in a couple of minutes. The version is widely available through licensed clinical use; the original paper is in the British Journal of Psychiatry. Many clinicians will be glad to integrate a self-report functional measure into your visits if you bring one.
How Frida thinks about it
We use brief functional self-report items aligned with WSAS domains as part of our weekly tracking. Combined with daily symptom and sleep tracking, this lets the user and their clinician see whether life domains are improving even when symptom scores are stable. Recovery is multidimensional; measurement should be too.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.